title: Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation.
abstract: Transmissible spongiform encephalopaties are caused by an extracellular surface protein, the scrapie prion protein (PrPsc), which is an aberrant form of normal and functional cellular PrP (PrPc). The pathological hallmarks of these diseases are the accumulation and deposition of PrPsc in the form of amyloid fibrils in the central nervous system (Tateishi et al., 1988), similar to amyloid-beta (Abeta) protein in Alzheimer's disease (AD). In some patients, Abeta and prion pathology can coexist (Hainfellner et al., 1998), and a common spatial pattern of protein deposition has been described (Armstrong et al., 2001). In addition, it is well-known that acetylcholinesterase (AChE) colocalizes with Abeta deposits of brains in AD patients and accelerates assembly of Abeta peptides through the peripheral site of the enzyme (Inestrosa et al., 1996). The aim of the present study was to analyze time course and concentration dependence of the AChE proaggregating effect on synthetic peptide-spanning residues 106-126 of human PrP (PrP106-126) and the reversion of this effect by different AChE inhibitors (AChEIs).
authors.affiliation: Departamento de Farmacologia, de Terapèutica, i de Toxicologia, Instituto Neurociències, UAB, Barcelona, Spain. Victoria.Clos@uab.es
authors.forename: M V
authors.initials: MV
authors.lastname: Clos
authors.forename: M
authors.initials: M
authors.lastname: Pera
authors.forename: M
authors.initials: M
authors.lastname: Ratia
authors.forename: S
authors.initials: S
authors.lastname: Román
authors.forename: P
authors.initials: P
authors.lastname: Camps
authors.forename: D
authors.initials: D
authors.lastname: Muñoz-Torrero
authors.forename: L
authors.initials: L
authors.lastname: Colombo
authors.forename: M
authors.initials: M
authors.lastname: Salmona
authors.forename: A
authors.initials: A
authors.lastname: Badia
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism*; D000470:Alkaloids; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D007700:Kinetics; D010446:Peptide Fragments / Q000187:drug effects / Q000378:metabolism*; D011328:Prions / Q000187:drug effects / Q000378:metabolism*; D012608:Scrapie; D012717:Sesquiterpenes / Q000494:pharmacology
chemical_list: D000470:Alkaloids; D002800:Cholinesterase Inhibitors; D010446:Peptide Fragments; D011328:Prions; D012717:Sesquiterpenes; C082632:prion protein (106-126); C050426:huperzine A; D000110:Acetylcholinesterase